




The relative strengths and weaknesses of Nabriva Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nabriva Therapeutics plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Nabriva Therapeutics plc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 296%, being 45% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	93,839
Cost of Goods Sold	0
Intangible Assets	172
Liabilities, Current	13,260
Liabilities, Non-Current	435
Other Assets	425
Other Compr. Net Income	17
Other Expenses	1,398
Other Liabilities	0
Other Net Income	6,129
Other Revenues	0
Property and Equipment	1,327
Research and Development	49,615
Selling, General and Administrative Expense	29,472

Output Variable	Value in 1000 USD
Assets	95,763
Liabilities	13,695
Expenses	80,485
Revenues	0
Stockholders Equity	82,068
Net Income	-74,356
Comprehensive Net Income	-74,348
BaseVar	98,044
ECR before LimitedLiability	191%
Economic Capital Ratio	296%